B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease

The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, according to the global phase III MAJESTY trial. By week 104, 37% of patients achieved remission.